Navigation Links
Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA)
Date:3/8/2011

is available in 50-unit and 100-unit vials, which Merz believes may allow for more precise billing and reduce wastage.

IMPORTANT SAFETY INFORMATIONWARNING: Distant Spread of Toxin EffectPostmarketing reports indicate that the effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and at lower doses.CONTRAINDICATIONSXEOMIN is contraindicated in patients with a known hypersensitivity to the active substance botulinum toxin type A or to any of the components in the formulation and in the presence of infection at the proposed injection site(s).

WARNINGS AND PRECAUTIONS

  • The potency units of XEOMIN are not interchangeable with other preparations of botulinum toxin products.  Therefore, units of biological activity of XEOMIN cannot be compared to or converted into units of any other botulinum toxin products.
  • Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea). If serious and/or immediate hypersensitivity reactions occur further injection of
    '/>"/>

  • SOURCE Merz Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
    2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
    4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
    5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
    8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
    10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
    11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... Breckenridge Pharmaceutical, Inc. announced today that it ... Pvt. Ltd. ( Hyderabad, India ) under ... ANDAs.  Under the terms of the agreement, MSN will ... for the U.S. market, and Breckenridge will market and ... have agreed to develop an oral antibiotic with current ...
    (Date:12/19/2014)... 19, 2014  Monarch America Inc. (OTCQB: CANK) ("Monarch ... pleased to provide this review of the Company,s recent ... "Over this past year, we achieved many ... extremely proud to say that Monarch America is in ... has ever been," stated Eric Hagen , CEO ...
    (Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/942kh3/micro_market ) ... Market Monitor: North American Dermatology Diagnostic Devices Market" ... http://photos.prnewswire.com/prnh/20130307/600769 Cosmetic surgeries ... resulted in fueling the overall demand of the ... these dermatology devices is to assist in identifying ...
    Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3
    ... ... - Spreads Messages of Hope to Others with Diabetes and Steers Toward Its ... of Tour de France Competition, BRIDGEWATER, N.J., April 2, 2008 ,Sanofi-aventis announced today ... of,Team Type 1, a team of amateur and professional cyclists living with type 1,diabetes., ...
    ... Therapeutics,Inc. (CTI) (Nasdaq: CTIC ; MTA) today ... for review CTI,s Marketing Authorization,Application (MAA) for XYOTAX(TM) ... non-small cell lung cancer (NSCLC),with ECOG (Eastern Cooperative ... MAA at the beginning of March. The validation ...
    Cached Medicine Technology:Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R) 2Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R) 3Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R) 4Elite Team of Cyclists with Type 1 Diabetes Powers Forward in 2008 Sponsored by Rapid-Acting Insulin Apidra(R) 5European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review 2European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review 3European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review 4
    (Date:12/22/2014)... Physicians in China are most eagerly ... of non-Hodgkin’s lymphoma (NHL), according to a new report ... consulting firm. MabThera is the only biologic available to ... form of NHL. , According to Kantar Health’s report, ... of NHL in China has been growing and is ...
    (Date:12/22/2014)... 2014 Give a loved one the ... of health and vitality. , For a limited time, ... anti-aging formulas in special Holiday Wellness gift packages at ... , Each bottle contains cutting-edge, proven nutritional support for ... as well as we age. , Joint ...
    (Date:12/22/2014)... Austin, Texas (PRWEB) December 22, 2014 ... hustle and bustle of Black Friday shopping and opted ... publishing and marketing education company, for their 5th annual ... Marketer charged just $7 to attend the 5 ... sales that they promptly donated to support two Central ...
    (Date:12/22/2014)... 22, 2014 NAPW honors ... Woman of the Year. She is recognized with this ... most recognized networking organization of professional women in the ... Association of Professional Women is a vibrant networking community ... , Ms. Kreider is passionate and committed to best ...
    (Date:12/21/2014)... In this report, the global powered ... product, and application. The market, by power source, ... By product, the market covers the handpieces; power ... market is further subdivided into drills, saws, reamers, ... shavers, wire/pin drivers, and others. Moreover, the power ...
    Breaking Medicine News(10 mins):Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4
    ... May 6 Volcano Corporation (Nasdaq: VOLC ... of products for the diagnosis and treatment of coronary ... be participating in the Bank of America and Merrill ... presentation by Scott Huennekens, president and chief executive officer, ...
    ... Incorporated has initiated a voluntary, nationwide recall of one lot ... healthcare professionals as an aid in the diagnosis of myocardial ... to reports of low recovery of quality control samples containing ... affected lot. Although there have been no reported issues ...
    ... HOUSTON - A newly discovered gene known as DEAR1 is ... local recurrence-free survival in early-onset breast cancer, a research team ... Anderson Cancer Center reports in the journal PLoS Medicine ... because so many young women have recurrences in the breast, ...
    ... The Mobile Massage Team ( www.mobilemassageteam.com ), a ... programs, promotional events, and special affairs, today announced that the ... Annual GlobalFit Worksite Wellness Summit ( http://www.globalfit.com/summit/ ... Down Town Club in Center City Philadelphia. Team members ...
    ... - Leadership in Fight Against Tobacco Recognized Nationally -WASHINGTON, May ... of Greenfield, Ind., has been named the National Youth Advocate ... her leadership in the fight against tobacco. Emily is being ... 6) with four regional winners and a group winner. (Logo: ...
    ... released today by Ernst Berndt and Mark Trusheim of ... that eliminating FDA,s preemption protection would decrease patients, access ... reduce medical device industry employment. The paper, ... Devices on Patients, Innovation and Jobs," comes as ...
    Cached Medicine News:Health News:Volcano Corporation Presentation at Bank of America/Merrill Lynch Conference to be Webcast 2Health News:Biosite Incorporated Issues Voluntary, Nationwide Recall for Cardiac Marker Test 2Health News:Novel gene predicts local recurrence in early onset breast cancer 2Health News:Novel gene predicts local recurrence in early onset breast cancer 3Health News:Campaign for Tobacco-Free Kids Honors Emily Kile, Greenfield, IN, as National Youth Advocate of the Year 2Health News:Removing Medical Device Preemption Impacts Jobs, Health Care Costs, Patient Access 2
    ... TOPS is a support catheter which assists ... angioplasty or stenting. The spiral catheter offers ... with .014 to .018 steerable guidewires to ... occlusion is crossed, TOPS is withdrawn while ...
    ... are indicated for the removal ... thrombi from vessels in the ... also be used for temporary ... of fluids, and blood sampling. ...
    Introduced more than 30 years ago by Dr. Thomas J. Fogarty, these embolectomy catheters are indicated for the removal of fresh, soft emboli and thrombi from vessels in the arterial system....
    The new XMI catheter incorporates the best in catheter technology to ,provide exceptional handling characteristics comparable to todays balloon catheters and stent delivery systems....
    Medicine Products: